ArticleTherapeutic advances in medical oncology2026
CD39+CD8+ T cell infiltration is associated with clinical outcomes of subsequent immunotherapy in advanced EGFR-mutant non-small cell lung cancer.
Article in Therapeutic advances in medical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Immunotherapy has demonstrated limited efficacy in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC), often due to an immunosuppressive tumor microenvironment (TME). The clinical significance of the CD39-adenosine pathway in this refractory setting remains unclear. Objective: To explore the role of the CD39-adenosine pathway, especially CD39, in EGFR-mutant (EGFR-Mu) NSCLC patients who received immunotherapy as a second or later-line treatment. Design: In this retrospective study, clinical characteristics, treatment regimens, and efficacy endpoints (progression-free survival (PFS) and objective response rate (ORR)) were collected. We analyzed the correlation between CD39 expression, CD39 Methods: We retrospectively evaluated EGFR-Mu NSCLC patients receiving later-line immune checkpoint inhibitors (ICIs) at Jinling Hospital, alongside The Cancer Genome Altas (TCGA) cohort data. TME phenotyping (CD39, CD73, ADORA1, and CD39 Results: Database and clinical samples analyses revealed that expression of CD39 and CD73 was significantly increased in EGFR-Mu NSCLC samples compared to EGFR wild-type (EGFR-WT). However, Immunofluorescence (IF) results showed that the infiltration rate of CD39 Conclusion: Our exploratory findings suggest that CD39
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.